Loading…
IN8bio, Inc. is projected to decline to $0.9089 by 2027, a -5% move from its current price of $0.96. INAB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.9334 | $0.9601 | $0.9875 | +0.01% |
| Aug 6 | $0.9226 | $0.9601 | $0.9992 | +0.01% |
| Aug 7 | $0.9144 | $0.9602 | $1.01 | +0.02% |
| Aug 8 | $0.9076 | $0.9602 | $1.02 | +0.02% |
| Aug 9 | $0.9016 | $0.9603 | $1.02 | +0.03% |
| Aug 10 | $0.8963 | $0.9604 | $1.03 | +0.04% |
| Aug 11 | $0.8914 | $0.9604 | $1.03 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8914 | $0.9604 | $1.03 | +0.04% |
| Week 2 | $0.8646 | $0.9608 | $1.07 | +0.09% |
| Week 3 | $0.8447 | $0.9613 | $1.09 | +0.13% |
| Week 4 | $0.8284 | $0.9617 | $1.12 | +0.17% |
| Week 5 | $0.8143 | $0.9621 | $1.14 | +0.22% |
| Week 6 | $0.8017 | $0.9625 | $1.16 | +0.26% |
| Week 7 | $0.7904 | $0.9629 | $1.17 | +0.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc.
in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
IN8bio, Inc. (INAB) currently trades at $1.11 per share, with a market capitalization of $10.64M and a market rank of 4845. The stock’s price trajectory is reflected in a year-by-year forecast that begins neutral in 2026 and grows progressively more bullish toward 2050.
The forecast includes a wide range of outcomes by year, with long-run upside potential indicated by a peak average around $3.61 in 2050 and a max forecast as high as $6.69.
A major floor 23.1% below — a decisive break under it would weaken the trend.
Support has flipped 7.8% overhead — reclaiming it would be bullish.
The nearest ceiling, 54.2% above — a clean break opens room to run.
A major ceiling 94.8% above — clearing it would confirm fresh momentum.
Key INAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.10 | Sell | $1.09 | Sell |
| MA 10 | $1.16 | Sell | $1.15 | Sell |
| MA 20 | $1.27 | Sell | $1.24 | Sell |
| MA 50 | $1.42 | Sell | $1.36 | Sell |
| MA 100 | $1.49 | Sell | $1.50 | Sell |
| MA 200 | $1.70 | Sell | $2.12 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 24.62 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -142.55 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -28.13 | Sell |
| Bollinger %B (20,2) | 0.03 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.75 | Sell |
| Awesome (5,34) | -0.24 | Sell |
| Ultimate (7,14,28) | 15.15 | Buy |
| Momentum (10) | -0.30 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 1.03 | Sell |
| ADX (14) | 27.39 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is bearish, with RSI14 at 30. The stock remains trading below key moving averages, with SMA50 at $1.46 and SMA200 at $1.73, suggesting near-term weakness. Support is identified at $1.19 and resistance at $1.48, framing the current trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.96 | $0.96 | $1.20 | 0% | Neutral | |
| $0.7229 | $0.9089 | $1.21 | -5% | Neutral | |
| $0.8676 | $1.12 | $1.55 | +17% | Neutral | |
| $0.9048 | $1.20 | $1.71 | +25% | Bullish | |
| $0.9014 | $1.22 | $1.79 | +27% | Bullish | |
| $0.9066 | $1.25 | $1.87 | +30% | Bullish | |
| $0.8251 | $1.16 | $1.77 | +21% | Bullish | |
| $0.8472 | $1.21 | $1.88 | +26% | Bullish | |
| $0.8536 | $1.24 | $1.96 | +29% | Bullish | |
| $0.8782 | $1.30 | $2.08 | +35% | Bullish | |
| $1.02 | $1.62 | $2.76 | +68% | Bullish | |
| $1.76 | $3.15 | $5.89 | +228% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.96 | $0.96 | $1.16 | +0.00% |
| September 2026 | $0.7973 | $0.9435 | $1.15 | -1.72% |
| October 2026 | $0.81 | $0.9654 | $1.19 | +2.32% |
| November 2026 | $0.8261 | $0.9903 | $1.23 | +2.58% |
| December 2026 | $0.7979 | $0.9617 | $1.20 | -2.89% |
Click any year to see its month-by-month INAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, INAB is projected to trade between $0.96 and $1.20, averaging $0.96 — a potential gain of 0% from today's $0.96. A consolidation phase looks the most probable path here.
IN8bio, Inc.'s 2027 outlook centres on $0.9089, within a $0.7229 to $1.21 range. That is -5% versus the projected 2026 average. That marks a -5% change versus current levels. Price action looks broadly range-bound.
By 2028, INAB could reach as high as $1.55, with a base case around $1.12 and support toward $0.8676 — roughly +17% from $0.96. A consolidation phase looks the most probable path here.
Expect INAB to range from $0.9048 to $1.71 through 2029. The $1.20 average target implies a +25% move from current prices. That is up +7% on the projected 2028 average. Momentum favours further upside here.
The INAB price prediction for 2030 points to an average of $1.22 (low $0.9014, high $1.79) — a potential gain of +27% on today's $0.96. Buyers look set to stay in control over this stretch.
In 2031, INAB is projected to trade between $0.9066 and $1.87, averaging $1.25 — a potential gain of +30% from today's $0.96. That is up +3% on the projected 2030 average. Momentum favours further upside here.
IN8bio, Inc.'s 2032 outlook centres on $1.16, within a $0.8251 to $1.77 range. That is -7% versus the projected 2031 average. That marks a +21% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, INAB could reach as high as $1.88, with a base case around $1.21 and support toward $0.8472 — roughly +26% from $0.96. Momentum favours further upside here.
Expect INAB to range from $0.8536 to $1.96 through 2034. The $1.24 average target implies a +29% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The INAB price prediction for 2035 points to an average of $1.30 (low $0.8782, high $2.08) — a potential gain of +35% on today's $0.96. Momentum favours further upside here.
In 2040, INAB is projected to trade between $1.02 and $2.76, averaging $1.62 — a potential gain of +68% from today's $0.96. That is up +25% on the projected 2035 average. Buyers look set to stay in control over this stretch.
IN8bio, Inc.'s 2050 outlook centres on $3.15, within a $1.76 to $5.89 range. That is up +95% on the projected 2040 average. That marks a +228% change versus current levels. Momentum favours further upside here.
Investing $1,000 in INAB today (≈ 1,041.666667 INAB) could be worth
$3,281.79
+$2,281.79 (+228%) by 2050 · US Dollar
Based on the average projected INAB price of $3.15 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INABwould be worth at today's price.
$1,000 invested in INAB on Jul 31, 2025 (≈ 469.483543 INAB) would be worth
$450.7
-$549.3 (-54.9%) today · 0.45× · US Dollar
Based on a INAB entry price of $2.13 vs. today's $0.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.2 | $800 | -20.0% |
| 1 month ago | $1.42 | $676.06 | -32.4% |
| 3 months ago | $1.5 | $640 | -36.0% |
| 6 months ago | $1.96 | $489.8 | -51.0% |
| 1 year ago | $2.13 | $450.7 | -54.9% |
| All time (5.0y) ago | $296.4 | $3.24 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INAB forecast.
Our base-case forecast reaches $1.90 around 2050.
Implied market cap at $1.90: $18.22M
The multi-year outlook shows a path from neutral to bullish over time. The 2026 forecast yields an average price of $1.11 with 0% ROI, while 2027 shows a slight dip to an average of $1.06 with a -4.6% ROI. The momentum shifts higher starting in 2028 (avg $1.30, ROI 17.2%), then stronger gains into 2029 (avg $1.38, ROI 24%) and 2030 (avg $1.41, ROI 26.8%).
The uptrend continues through 2031 (avg $1.44, ROI 30.1%), 2032 (avg $1.34, ROI 20.3%), 2033 (avg $1.41, ROI 26.6%), 2034 (avg $1.43, ROI 29.2%), and 2035 (avg $1.49, ROI 34.3%). The forecast remains bullish thereafter, with 2040 (avg $1.87, ROI 68.7%) and 2050 (avg $3.61, ROI 225.3%) signaling substantial long-run upside. These figures are estimates and not guarantees; actual results may differ and depend on a variety of factors.
Tap a question to reveal the answer.
Avg $1.41, Min $1.04, Max $2.05, ROI 26.8%.
The forecast shows a neutral stance in 2026 with avg $1.11 and ROI 0%, a dip in 2027 (avg $1.06, ROI -4.6%), followed by bullish momentum in later years, culminating in an avg $3.61 and ROI 225.3% in 2050. These are estimates, not guarantees.
Current price is $1.11 and market capitalization is $10.64M.
Sentiment is BEARISH with RSI14 at 30. The price is below SMA50 ($1.46) and SMA200 ($1.73). Support is at $1.19 and resistance at $1.48, with a 30-day range from $0.9259 to $1.33 and annualized volatility of 50%.
2040 avg $1.87 with ROI 68.7%; 2050 avg $3.61 with ROI 225.3%. These represent long-run upside in the provided forecast.
IN8bio, Inc. Community Discussion
0Share your IN8bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.